Prognostic factors for treatment of malignant lymphoma in dogs

Erik Teske From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by Erik Teske in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Peter van Heerde From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by Peter van Heerde in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Gerard R. Rutteman From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by Gerard R. Rutteman in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Ilene D. Kurzman From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by Ilene D. Kurzman in
Current site
Google Scholar
PubMed
Close
 MS, EdD
,
Peter F. Moore From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by Peter F. Moore in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
, and
E. Gregory MacEwen From the Department of Clinical Sciences of Companion Animals, Utrecht University, 3508 Utrecht, The Netherlands (Teske, Rutteman); the Department of Pathology, The Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands (van Heerde); the Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706 (Kurzman, MacEwen); and the Department of Veterinary Pathology, School of Veterinary Medicine, University of California, Davis, CA 95616 (Moore).

Search for other papers by E. Gregory MacEwen in
Current site
Google Scholar
PubMed
Close
 VMD

Summary

Pretreatment characteristics of 138 dogs with malignant lymphoma were analyzed to determine prognostic factors associated with outcome (ie, complete response rate, time to relapse after complete response, survival time). Dogs were all treated for 10 weeks, using a standard induction chemotherapy protocol, and were then given asparaginase weekly. Once the disease became progressive, second-line chemotherapy was instituted.

Age, sex, weight, clinical stage, performance grade, immunophenotype, and malignancy grade assigned according to the National Cancer Institute's Working Formulation were not associated with complete response rate. However, malignancy grade assigned according to the Kiel classification was found to be associated with complete response rate; dogs with high-grade malignancies had a significantly higher complete response rate than did dogs with low-grade malignancies.

By means of multivariate analysis, clinical stage and immunophenotype were found to be prognostic factors for time to relapse (among dogs that had had a complete response) and survival time. In addition, malignancy grade assigned according to the Kiel classification was found to be a prognostic factor for time to relapse; whereas, malignancy grade assigned according to the Working Formulation was determined to be a prognostic factor for survival time.

Summary

Pretreatment characteristics of 138 dogs with malignant lymphoma were analyzed to determine prognostic factors associated with outcome (ie, complete response rate, time to relapse after complete response, survival time). Dogs were all treated for 10 weeks, using a standard induction chemotherapy protocol, and were then given asparaginase weekly. Once the disease became progressive, second-line chemotherapy was instituted.

Age, sex, weight, clinical stage, performance grade, immunophenotype, and malignancy grade assigned according to the National Cancer Institute's Working Formulation were not associated with complete response rate. However, malignancy grade assigned according to the Kiel classification was found to be associated with complete response rate; dogs with high-grade malignancies had a significantly higher complete response rate than did dogs with low-grade malignancies.

By means of multivariate analysis, clinical stage and immunophenotype were found to be prognostic factors for time to relapse (among dogs that had had a complete response) and survival time. In addition, malignancy grade assigned according to the Kiel classification was found to be a prognostic factor for time to relapse; whereas, malignancy grade assigned according to the Working Formulation was determined to be a prognostic factor for survival time.

Advertisement